Literature DB >> 6128791

Nonopiate effects of dynorphin and des-Tyr-dynorphin.

J M Walker, H C Moises, D H Coy, G Baldrighi, H Akil.   

Abstract

Intracerebroventricular administration of dynorphin produced potent and long-lasting effects on motor function and the electroencephalogram in rats. In addition, local iontophoretic or pressure ejection of dynorphin consistently inhibited hippocampal unit activity. None of these effects were significantly affected by naloxone even at high doses. Moreover, a fragment of dynorphin that failed to displace any of a number of tritiated narcotics from rat brain homogenates produced similar effects on these physiological measures in vivo. On the basis of a variety of criteria for "opiate action," the results suggest that a second biologically active site within the dynorphin sequence is capable of quite potent but nonopiate effects.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6128791     DOI: 10.1126/science.6128791

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  42 in total

1.  Proportions of Ca2+ channel subtypes in chick or rat P2 fraction and NG108-15 cells using various Ca2+ blockers.

Authors:  Z Yu-an; T Imanishi; T Wada; S Ichida
Journal:  Neurochem Res       Date:  1999-08       Impact factor: 3.996

Review 2.  Central non-opioid physiological and pathophysiological effects of dynorphin A and related peptides.

Authors:  V K Shukla; S Lemaire
Journal:  J Psychiatry Neurosci       Date:  1992-09       Impact factor: 6.186

Review 3.  Dynorphin A analogs for the treatment of chronic neuropathic pain.

Authors:  Sara M Hall; Yeon Sun Lee; Victor J Hruby
Journal:  Future Med Chem       Date:  2016-01-29       Impact factor: 3.808

4.  Prodynorphin mutations cause the neurodegenerative disorder spinocerebellar ataxia type 23.

Authors:  Georgy Bakalkin; Hiroyuki Watanabe; Justyna Jezierska; Cloë Depoorter; Corien Verschuuren-Bemelmans; Igor Bazov; Konstantin A Artemenko; Tatjana Yakovleva; Dennis Dooijes; Bart P C Van de Warrenburg; Roman A Zubarev; Berry Kremer; Pamela E Knapp; Kurt F Hauser; Cisca Wijmenga; Fred Nyberg; Richard J Sinke; Dineke S Verbeek
Journal:  Am J Hum Genet       Date:  2010-10-28       Impact factor: 11.025

Review 5.  Pathobiology of dynorphins in trauma and disease.

Authors:  Kurt F Hauser; Jane V Aldrich; Kevin J Anderson; Georgy Bakalkin; MacDonald J Christie; Edward D Hall; Pamela E Knapp; Stephen W Scheff; Indrapal N Singh; Bryce Vissel; Amina S Woods; Tatiana Yakovleva; Toni S Shippenberg
Journal:  Front Biosci       Date:  2005-01-01

Review 6.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

7.  Two different types of dynorphin-A-immunoreactive terminals in rat substantia nigra.

Authors:  R Riesenberg; C Nitsch
Journal:  Cell Tissue Res       Date:  1990-07       Impact factor: 5.249

Review 8.  Pronociceptive actions of dynorphin via bradykinin receptors.

Authors:  Josephine Lai; Miaw-chyi Luo; Qingmin Chen; Frank Porreca
Journal:  Neurosci Lett       Date:  2008-04-08       Impact factor: 3.046

9.  Dynorphin opioid peptides enhance acid-sensing ion channel 1a activity and acidosis-induced neuronal death.

Authors:  Thomas W Sherwood; Candice C Askwith
Journal:  J Neurosci       Date:  2009-11-11       Impact factor: 6.167

10.  Neuropathic plasticity in the opioid and non-opioid actions of dynorphin A fragments and their interactions with bradykinin B2 receptors on neuronal activity in the rat spinal cord.

Authors:  Kirsty Bannister; Yeon Sun Lee; Leonor Goncalves; Frank Porreca; Josephine Lai; Anthony H Dickenson
Journal:  Neuropharmacology       Date:  2014-06-14       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.